We are live on ! Find out more
PVCT

PROVECTUS BIOPHARMACEUTICALS, INC. (DE)
PVCT

Delisted

PVCT was delisted on the 13th of October, 2016.

Back to rankings

7 hedge funds and large institutions have $20.4K invested in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) in 2025 Q3 according to their latest regulatory filings, with funds opening new positions, 1 increasing their positions, reducing their positions, and closing their positions.

New
Increased
Maintained
Reduced
Closed

20% more capital invested

Capital invested by funds: $17.1K → $20.4K (+$3.34K)

0% more funds holding

Funds holding: 7 → 7 (0)

Holders
7
Holders Change
–
Holders Change %
0%
% of All Funds
0.09%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
1
Reduced
–
Closed
–
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
WPA
Wealth Preservation Advisors
Tennessee
+$53

Top Sellers

No sellers this quarter
Name Holding Trade Value Shares
Change 		Change in
Stake
HFBOT
1
Home Federal Bank of Tennessee
Tennessee
$8.9K – – –
WPA
2
Wealth Preservation Advisors
Tennessee
$4.68K +$53 +600 +1%
AW
3
Atlas Wealth
Ohio
$2.37K – – –
ACM
4
Academy Capital Management
Texas
$1.78K – – –
LIA
5
LBMC Investment Advisors
Tennessee
$1.78K – – –
FS
6
Financial Symmetry
North Carolina
$907 – – –

PVCT Hedge Fund Activity: Q3 2025 in Review

7 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) for Q3 2025, worth a combined $20.4K — up 20% from $17.1K a quarter earlier.

Fund positioning in PVCT was balanced in Q3 2025: 0 funds opened new positions, 0 closed out, 1 added to existing stakes and 0 trimmed.

The largest buyer was Wealth Preservation Advisors, adding an estimated $53.

  • 7 institutional investors held PROVECTUS BIOPHARMACEUTICALS, INC. (DE) (PVCT) as of Q3 2025, unchanged from Q2 2025.
  • Funds reported $20.4K of PROVECTUS BIOPHARMACEUTICALS, INC. (DE) stock for Q3 2025, up 20% quarter-over-quarter.
  • 0 funds opened new PROVECTUS BIOPHARMACEUTICALS, INC. (DE) positions in Q3 2025 and 0 closed out.
  • The largest PROVECTUS BIOPHARMACEUTICALS, INC. (DE) buyer in Q3 2025 was Wealth Preservation Advisors, an estimated $53 added.

Based on aggregated 13F filings for Q3 2025.